Avalglucosidase alfa (GZ402666)
DrugPharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
Other names: Nexviadyme®
NCT Number: NCT05164055
This long-term open label safety and efficacy study is intended to follow up, and to provide post-trial access to enzyme replacement therapy (ERT) with avalglucosidase alfa to patients with Pompe disease in France who have completed Study EFC14028, LTS13769, or ACT14132, from market authorization until reimbursement of avalglucosidase alfa in France or until September 2026, whichever comes first.
- Study visit frequency: every 2 weeks
This study is active but is not currently recruiting participants.
6 month and older
All sexes
Interventional
Phase 4
Investigational Site Number : 2500004, Bordeaux, France
Treatment duration approximately 4 years and 3 months: until reimbursement of avalglucosidase alfa in France or until September 2026, whichever comes first
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Pharmaceutical form: Sterile lyophilized powder Route of administration: intravenous (IV) infusion
Other names: Nexviadyme®
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
The primary measurement is the distance in meters walked by the participant on a flat, hard surface in 6 minutes. The distance walked in meters will be recorded and the corresponding percent predicted value will be calculated. The greater the distance (that a participant could walk in 6 minutes), the greater the endurance.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
The QMFT is an observer administered test to evaluate changes in motor function. QMFT comprises of 16 items specifically difficult for participants with Pompe disease. Each item is scored separately on a 5-point ordinal scale (ranged from 0 to 4, higher score indicated better outcome). Total QMFT score is obtained by adding the scores of all items and ranged from 0 (unable to perform motor function tests) to 64 (normal muscle function), higher score represented better outcome.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
FVC is a standard pulmonary function test used to quantify respiratory muscle weakness. FVC is the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position, also tested in supine position. Percent of predicted FVC = (actual FVC measurement)/(predicted value of FVC) * 100.
Maximum Inspiratory Pressure (MIP) is a quick and non-invasive test to measure strength of inspiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MIP refers to how much air pressure force an individual creates by inhaling through the mouth as hard as possible.
Maximum Expiratory Pressure (MEP) is a quick and non-invasive test to measure strength of expiratory muscles, primarily diaphragm, and allows for assessment of ventilatory failure, restrictive lung disease and respiratory muscle strength. MEP is the greater pressure generated during maximal expiration.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
SF-12, a 12 item-questionnaire, used to assess health-related quality of life in participants aged >=18 years at screening/baseline. SF-12 consisted of 12 items, which were categorized into eight domains (subscales) of functioning and well-being: physical functioning, role-physical, role emotional, mental health, bodily pain, general health, vitality and social functioning, with each domain score ranged from 0 (poor health) to 100 (better health), higher scores indicated good health condition. These eight domains were further summarized into 2 summary scores, physical component summary (PCS) and mental component summary (MCS). The score range for each of these 2 summary scores was from 0 (poor health) to 100 (better health), higher scores indicated a better health-related quality of life.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
The 24-hour recall PDSS (V1.1) is a self-administered questionnaires specifically designed to capture the symptoms impacts relevant to patients with LOPD. The PDSS includes 12 questions with responses on a scale from 0 (none) to 10 (as bad as I can imagine) The data from PDSS scale will be analyzed separately and as a composite with PDIS scale.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
The 24-hour recall PDIS (V1.2) is a self-administered questionnaires specifically designed to capture disease impacts relevant to patients with LOPD. The PDIS includes 15 questions with varying scales implemented depending on question type. The data from PDIS scale will be analyzed separately and as a composite with PDSS scale.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
The Pompe-PEDI consists of a Functional Skills Scale and a Caregiver Assistance Scale. Both scales have 3 domains: self-care; mobility; and social function. The Mobility Domain was selected to measure change in mobility secondary to changes in muscle strength. The domain consists of 160 mobility items.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
The 23item PedsQL Generic Core Scale encompasses 4 subscales including physical, emotional, school, and social functionings. Scores are transformed to a 0-100 scale, higher scores indicate better HRQOL.
Infant scale will not be used since this is a scale for up to 24 months of age and patients are older now than that.
Time frame: From study enrolment to the final study visit/telephone contact, up to 4 years and 3 months (at enrolment and every 6 months)
Left Ventricular Mass Index (LVMI) equivalent to mean age specific LVMI plus 2 standard deviations.
Genzyme, a Sanofi Company
Industry
A French Multicenter Open Label Phase 4 Extension Study of Long-term Safety and Efficacy in Patients With Pompe Disease Who Previously Participated in Avalglucosidase Alfa Development Studies in France
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04848779
Brain Diseases, Brain Diseases, Metabolic
Hawthorne, New York, United States
View Trial DetailsNCT04910776
Brain Diseases, Brain Diseases, Metabolic
Stanford, California, United States
View Trial DetailsNCT04093349
Acid Maltase Deficiency, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT00231400
Brain Diseases, Brain Diseases, Metabolic
Birmingham, Alabama, United States
View Trial Details